DRMA Stock Overview
A late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Dermata Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.08 |
| 52 Week High | US$13.35 |
| 52 Week Low | US$1.05 |
| Beta | 0.79 |
| 11 Month Change | -30.77% |
| 3 Month Change | -41.30% |
| 1 Year Change | -89.87% |
| 33 Year Change | -99.84% |
| 5 Year Change | n/a |
| Change since IPO | -99.91% |
Recent News & Updates
Shareholder Returns
| DRMA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.2% | -7.5% | -1.2% |
| 1Y | -89.9% | 14.1% | 30.4% |
Return vs Industry: DRMA underperformed the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: DRMA underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| DRMA volatility | |
|---|---|
| DRMA Average Weekly Movement | 18.8% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DRMA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DRMA's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 8 | Gerry Proehl | www.dermatarx.com |
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company’s lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions.
Dermata Therapeutics, Inc. Fundamentals Summary
| DRMA fundamental statistics | |
|---|---|
| Market cap | US$1.63m |
| Earnings (TTM) | -US$11.27m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs DRMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DRMA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$11.27m |
| Earnings | -US$11.27m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.46 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DRMA perform over the long term?
See historical performance and comparison